ストックスクリーナーアプリを入手
5.18
0.77%
-0.04
アフターアワーズ：
5.81
0.63
+12.16%
前日終値:
$5.22
開ける：
$5.23
24時間の取引高:
27,843
Relative Volume:
1.15
時価総額：
$20.97M
収益：
-
当期純損益:
$-30.85M
株価収益率:
-0.9104
EPS:
-5.6896
ネットキャッシュフロー:
$-13.20M
1週間 パフォーマンス:
-2.81%
1か月 パフォーマンス:
-64.18%
6か月 パフォーマンス:
-86.80%
1年 パフォーマンス:
-91.58%
1日の値動き範囲:
$5.00
$5.64
1週間の範囲:
$4.892
$5.64
52週間の値動き範囲:
$4.892
$75.50
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
名前
Tevogen Bio Holdings Inc
セクター
電話
646-807-8832
住所
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN
Compare TVGN vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
5.18 | 21.13M | 0 | -30.85M | -13.20M | -5.6896 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-03-04 | 開始されました | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc (TVGN) 最新ニュース
Tevogen Bio Regains Nasdaq Compliance After Reverse Split - TipRanks
Tevogen Bio regains Nasdaq compliance following reverse stock split - Investing.com
Tevogen Bio Holdings regains Nasdaq bid-price compliance after 1-for-50 reverse split - TradingView
Nasdaq restores TVGN listing after 1-for-50 reverse split (TVGN) - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
Tevogen regains compliance with Nasdaq minimum bid price requirement - TipRanks
Tevogen Bio Regains Compliance With Nasdaq Listing Rule - marketscreener.com
Tevogen Bio Holdings Regains Compliance with Nasdaq Listing Requirements - Quiver Quantitative
Tevogen clears Nasdaq's $1 stock-price rule, keeps listing - Stock Titan
Tevogen Bio Holdings Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Market Pulse: Why is Tevogen Bio Holdings Inc Equity Warrant stock going upWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Revenue Check: Why is Tevogen Bio Holdings Inc Equity Warrant stock going up - baoquankhu1.vn
TVGN Technical Analysis & Stock Price Forecast - Intellectia AI
Tevogen Bio Holdings Inc. Announces CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference 2026 on Data Engineering and AI - Quiver Quantitative
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026) - Finviz
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community ... - Caledonian Record
Microsoft FabCon puts Tevogen AI chief on two data engineering panels - Stock Titan
Neal Flomenberg sells Tevogen Bio Holdings (TVGN) shares for $6.6k - Investing.com
Tevogen Bio (TVGN) officer sells 972 shares to cover tax obligations - Stock Titan
Tevogen reports performance advancements for Tevogen.AI platform - TipRanks
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization - The Globe and Mail
Tevogen Bio Advances AI Drug Development Platform with Improved Predictive Accuracy for Target Identification - Quiver Quantitative
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics ... - Bluefield Daily Telegraph
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure - The Manila Times
Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure - 富途牛牛
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - Finviz
Wall Street Recap: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysisEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Tevogen Bio Holdings Inc. is considering the acquisition of Sciometrix and Clinicus platforms to enhance its monitoring capabilities for Long Covid. - Bitget
Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative
Long COVID ‘clinical emergency’: Tevogen develops T-cell therapy for 65% of U.S. - Stock Titan
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment - GlobeNewswire
Tevogen Bio Holdings Inc Share Price USD0.0001 - Hargreaves Lansdown
Tevogen appoints interim leaders across core business verticals - TipRanks
Tevogen Bio Holdings Inc. Appoints Interim Leaders to Drive Diversified Growth Strategy - Quiver Quantitative
Tevogen Names Leadership Team to Execute Diversified Growth Strategy - GlobeNewswire
Free cash flow of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Total liabilities & shareholders' equities of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Total debt of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Tevogen Bio Holdings Inc. Cash Flow – FWB:G280 - TradingView
Tevogen Bio Holdings Inc. Balance Sheet – FWB:G280 - TradingView
Total common shares outstanding of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Operating income of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Price to book ratio of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Price to sales ratio of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Total operating expenses of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
After tax other income/expense of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Net current asset value per share of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Enterprise value to EBITDA ratio of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Diluted earnings per share (diluted EPS) of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Price to cash flow ratio of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Tevogen Bio Holdings Inc (TVGN) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):